// App-Quantinova.ai

662 : In Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Imatinib (IM) and Chemotherapy in Combination Improve Remission Rate, Stem Cell Transplantation Rate and Long-Term Outcome

Researchers

Presenter

  • Chiara Cattaneo

Principal Investigators

  • Enrico Maria Pogliani

  • Manuela Tosi

  • Elena Oldani

  • Alessandro Rambaldi

  • Renato Bassan

  • Eros Di Bona

  • Claudio Romani

  • Vincenzo Cassibba

  • Agostino Cortelezzi

  • Francesco Mannelli

  • Fabio Ciceri

  • Daniele Mattei

  • Orietta Spinelli

Medical Centers

  • Hematology, Ospedale S. Bortolo, Vicenza, Italy

  • Hematology, Az. Osp. S. Croce e Carle, Cuneo, Italy

  • Division of Hematology, Ospedali Riuniti, Bergamo, Italy

  • UO oNcoematologia, IRCCS Ca Granda Ospedale Maggiore Policlinico and Universit degli Studi, Milano, Italy

  • Oncologia, Spedali Civili, Brescia, Italy

  • HSCT Adult Unit, Ospedale San Gerardo, Monza, Italy

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Hematology, Universita di Firenze, AOU Careggi, Firenze, Italy

  • Hematology, Ospedale Oncologico di Riferimento Regionale, Cagliari, Italy

  • Hematology, Ospedale del-Angelo, Mestre-Venezia, Italy

  • Hematology, Ospedale Civile, Bolzano, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Autophagy-related gene 5

  • Breakpoint Cluster Region

Drug/Treatment

  • Imatinib

  • IkT001

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved